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Abstract
Phlebotomy is often addressed as a crucial process in the pre-analytical phase, in which a large part of laboratory errors take place, but to date there 
is not yet a consolidated methodological paradigm. Seeking literature, we found 36 suitable investigations issued between 1996 and 2016 (April) 
dealing with the investigation of pre-analytical factors related to phlebotomy. We found that the largest part of studies had a cohort of healthy 
volunteers (22/36) or outpatients (11/36), with the former group showing a significantly smaller median sample size (N = 20, IQR: 17.5-30 and N = 
88, IQR: 54.5-220.5 respectively, P < 0.001). Moreover, the largest part investigated one pre-analytical factor (26/36) and regarded more than one 
laboratory test (29/36), and authors preferably used paired Student’s t-test (17/36) or Wilcoxon’s test (11/36), but calibration (i.e. sample size calcu-
lation for a detectable effect) was addressed only in one manuscript. The Bland-Altman plot was often the preferred method used to estimate bias 
(12/36), as well as the Passing-Bablok regression for agreement (8/36). However, often papers did assess neither bias (12/36) nor agreement (24/36). 
Clinical significance of bias was preferably assessed comparing to a database value (16/36), and it resulted uncorrelated with the size of the effect 
produced by the factor (P = 0.142). However, the median effect size (ES) resulted significantly larger if the associated factor was clinically significant 
instead of non-significant (ES = 1.140, IQR: 0.815-1.700 and ES = 0.349, IQR: 0.228-0.531 respectively, P < 0.001). On these evidences, we discussed 
some recommendations for improving methodological consistency, delivering reliable results, as well as ensuring accessibility to practical evidences.
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Introduction
The investigation of pre-analytical factors in labo-
ratory medicine is pivotal to improve the overall 
clinical laboratory quality, and in turn to ensure 
the patient safety (1). In this regard, phlebotomy is 
addressed as a crucial process in the pre-analytical 
phase, in which a large part of laboratory errors is 
thought to arise, having the potentialities to affect 
largest part of medical decisions (2,3). Indeed, 
apart from the provision with qualitatively appro-
priate supplies that depends on the healthcare 
service’s choice, there are no other means than the 
operator’s skills and compliance with standard 
procedures to ensure the adequate sample quality 
(4). As far as pre-analytics is a major concern in cur-
rent laboratory medicine and an issue for practi-
tioners and researchers, this field of investigation 
should be fostered in order to produce evidences 
for best practice (5,6). Indeed, unnecessarily com-
plicating the patient management without any ac-
tual improvement, or even oversimplifying and 
then flawing its safety, might undermine the op-
erator’s awareness of a mandatory and careful pre-
analytics. Carrying out a pre-analytical investiga-
tion poses some methodological concerns regard-
ing the statistical framework used to assess the in-
vestigated factor. Furthermore, with respect to 
phlebotomy, there are some more specific issues 
arising on the choice of the appropriate cohort, 
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the standardization of procedures and the deliver-
ability of results to non-academic readers. Thus, 
such studies should grant the highest reliability, 
whereby dispelling any doubt of misleadingness. 
Scope of the present paper is assessing the appro-
priateness of the methodology used to carry out a 
pre-analytical investigation of phlebotomy, fitting 
researchers with specific recommendations on 
study set up and delivery. Thereby, in this two-part 
paper, part I aimed to gather evidences through a 
review of available literature and summarizing evi-
dence, and part II is concerned with methodologi-
cal appropriateness and the choice of suitable pro-
cedures.
PART I – Evidences
Literature search and data analysis 
The literature database MEDLINE was searched us-
ing PubMed for papers issued in the last twenty 
years (January 1996 to April 2016). In order to 
structure the search, we first set a combination of 
keywords that targeted the general topic of pre-
analytics in laboratory (e.g. “laboratory test”, “pre-
analytic”, “biological OR individual”). Afterwards, 
we refined the search focusing on ten topics each 
of which addressed a pre-analytical aspect of phle-
botomy strictly related to the operator’s choice, 
and setting appropriate keywords (Table 1).
For each topic searched, suitable papers were ex-
tracted by deciding on the bases of the abstract 
content. Papers were considered suitable only if 
compliant with all the following requirements: a) 
were based on an experimental set up aimed to 
investigate one or more pre-analytical factors re-
lated to the procedure of blood drawing, b) re-
ported a quantitative effect (mean change and/or 
bias) with respect to clinical chemistry, haematol-
ogy and coagulation tests, c) assessed no other 
procedure for vein accessioning except venepunc-
ture. Thus, we excluded retrospective studies rely-
ing on mathematical models like regression, stud-
ies dealing with pre-analytics in metabolomics or 
biobanking, investigations comparing phleboto-
my to other drawing techniques (e.g. saline lock 
devices or intravenous catheters) as well as those 
assessing the effect of particular devices or materi-
als (e.g. kind of tube preservatives or infra-red vein 
finders). 
Finally, selected papers were evaluated with re-
spect to the experimental set up, sample size (N), 
kind of population used for the study (volunteers, 
donors, inpatients, outpatients), number of indi-
vidual laboratory tests evaluated, number of fac-
tors assessed, testing of data normality, descrip-
tive measures provided (central tendency, disper-
sion), measure of association between paired ob-
servations, methodology used for agreement and 
bias estimation, clinical significance assessment. 
Data were analysed with Microsoft Excel (Micro-
soft Corporation, USA) spreadsheet and StatsDi-
rect 2.7.2 (StatsDirect Ltd., UK) statistical package, 
representing relative frequencies as proportions 
according to the author guidelines (7). The nor-
mality of the data was tested by means of Shapiro-
Wilk’s test. Data dispersion was assessed using a 
dot-plot and represented by median and inter-
quartile range (IQR) accordingly. The statistical as-
sociation between qualitative variables was as-
sessed by means of the Fisher’s exact test or Fish-
er-Freeman-Halton test, or by the Spearman’s ρ 
between quantitative continuous variables. In-
Table 1. Keywords used for search refinement
Topic Keywords
Compliance to preparatory 
fasting Fasting, meal, diet
Body position Position, posture, postural changes
Tourniquet application Tourniquet, venous stasis
Needle gauge Needle gauge, bore size
Needle type (regular/
butterfly)
Butterfly needle, regular 
needle
Order of draw Order of draw, tube order, sample order
Antiseptic swabbing Disinfectant, alcohol use avoidance, swabbing
Mode of aspiration Mode of aspiration, vacuum
Discard tube Discard tube, first tube
Specimen handling Tube mixing, sample mixing
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stead, the Mann-Whitney U test was used to assess 
the association between a continuous and a quali-
tative variable (i.e. the effect of a factor on a medi-
an value). The effect size was estimated according 
to Spearman’s ρ for U-test, while the pairwise Co-
hen’s d was used for retrospective estimation of 
data available in the reviewed studies (8-10). Statis-
tical significance level was set at P < 0.05.
Search results
The search provided a total of 136 articles, of which 
36 resulted suitable and available for this study ac-
cording to the established criteria. Three more pa-
pers, which resulted potentially suitable, were not 
available through our local library service, and 
thus were excluded from this study. Some papers 
dealt with more than one topic in the same experi-
mental set up, so with respect to each single topic 
we found:
•	 4/36 (0.11) on “compliance to preparatory fast-
ing” (11-14) 
•	 4/36 (0.11) on “body position” (15-18) 
•	 6/36 (0.17) on “tourniquet application” (19-24) 
•	 2/36 (0.06) on “needle gauge” (25,26) 
•	 3/36 (0.08) on “needle type (regular or butter-
fly)” (27-29) 
•	 5/36 (0.14) on “order of draw” (15,19,30-32) 
•	 2/36 (0.06) on “antiseptic swabbing” (33,34)
•	 2/36 (0.06) on “mode of aspiration” (35,36)
•	 7/36 (0.19) on “discard tube” (37-43)
•	 4/36 (0.11) on “specimen handing (inversion)” 
(28,44-46)
Thus, it resulted 6/36 (0.17) papers issued by 1996-
2000, 5/36 (0.14) by 2001-2005, 7/36 (0.19) by 2006-
2010 and 18/36 (0.50) by 2011-2016 (up to March), 
issued in 17 different journals (Figure 1).
Sample size and study population
With respect to the sample size, 14/36 papers 
(0.39) had N ≤ 20, 6/36 (0.17) had N ≤ 30, and 16/36 
(0.44) had N > 30. In some studies where N > 30, 
the sample was partitioned into two or more sub-
groups on which the analysis was repeated inde-
pendently, so that the actual sample size varied 
according to the stratification (28,32,33,38,43,45). 
In only a single case (1/36, 0.03) the authors report-
ed the sample size was chosen basing on a prelim-
inary power analysis, otherwise no information re-
garding preliminary calculations was given (42). 
In 22/36 papers (0.61) the study population was 
represented by healthy volunteers, in 11/36 (0.30) 
by outpatients, in 1/36 by inpatients (0.03), in 1/36 
by blood donors (0.03) and in 1/36 it was not spec-
ified (0.03). Notably, with respect to the median 
sample size, it was N = 88 (IQR: 54.5 - 220.5) for 
studies using outpatients and N = 20 (IQR: 17.5 - 
30.0) for studies using volunteers, with the differ-
ence being statistically significant (P < 0.001, effect 
size ρ = 0.69).
Study design and data summarization
All the studies relied on the within-subjects or sin-
gle-group repeated-measures design. Particularly, 
26/36 (0.72) assessed 1 pre-analytical factor, while 
the remaining 10/36 (0.28) assessed 2 factors (e.g. 
tourniquet pressure and time). Besides, in 2 papers 
it was also assessed a third factor which was not 
related to phlebotomy (sample storage and data 
transportation respectively) (19,28). In 4/36 papers 
(0.11) the investigation regarded 1 laboratory test, 
in 15/36 (0.42) from 2 to 5 tests, in 12/36 (0.33) from 
6 to 24, while in 5/36 (0.14) 25 or more tests.  
In 28/36 papers (0.78) no normality test was men-
tioned or reported, while in 5/36 (0.14) the Kol-
mogorov-Smirnov or D’Agostino-Pearson’s test 
was used (without specifying which kind in one 
case), and in 3/36 (0.08) the paper was unclear re-
Figure 1. Number of issued papers by publication year.
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garding whether the test was performed and 
which one was adopted (15,19,25). Noteworthy, 
the use of normality test was not associated with 
the sample size, in that the frequency with which 
it was used in studies with N ≤ 20 and N > 20 did 
not differ statistically (P = 0.328).
The paired Student’s t-test was the most used sta-
tistical test for assessing the effect produced by 
the pre-analytical factor and it appeared in 17/36 
papers (0.47), while the non-parametric equivalent 
Wilcoxon’s paired-ranks test was used in 11/36 
(0.31). In this regard, in 2/36 cases (0.06) the au-
thors stated that Student’s or Wilcoxon’s test was 
chosen after the result of a normality test (12,46). 
In 4 papers (0.11) the authors used linear models to 
analyse their data, which were represented by par-
ametric or non-parametric (Friedman’s) 1-way 
ANOVA, or in 1 single case (0.03) by a linear mixed 
effect model (LMEM). Except when it was explicitly 
reported, the choice of a non-parametric instead 
of a parametric statistical test was made indepen-
dently from a sample size N ≤ 20 (P = 0.720), as 
well as a prior execution of a normality test (P = 
0.811). Noteworthy, although 29/32 papers (0.91) 
assessing more than 1 laboratory test used a 
2-sample location test (Student’s or Wilcoxon’s 
test), just 1/29 (0.04) corrected the α inflation by 
means of the Bonferroni method (41).
The mean was the central tendency measure most 
frequently used (26/36 papers, 0.75) to summarize 
data, and in 5/36 cases (0.14) it was used even 
when the statistic assessment was achieved by 
means of a non-parametric test (16,19,34,41,44). 
With respect to variability, the standard deviation 
was the measure most frequently used (19/36, 
0.53) along with the interquartile range (8/36, 
0.22), while just 4/36 (0.11) papers used the 95% 
confidence interval alongside the mean 
(28,36,41,42). Just 9/36 papers (0.25) provided the 
value of correlation between paired data, thereby 
allowing the retrospective estimation of the ob-
served effect size (21,22,25-27,29,39,40,43). With re-
spect to the appropriateness of summarization, 
considered as the kind of measure of central ten-
dency and dispersion adopted with a parametric 
or non-parametric test, it resulted independent 
from the journal that issued the research (P = 
0.676). 
Bias and clinical significance
The Bland-Altman analysis was used to estimate 
bias in 12/36 papers (0.33), followed by the per-
centage mean difference (8/36, 0.22) which repre-
sented the difference between baseline and treat-
ment values divided by the treatment value. Nota-
bly, in 12/36 papers (0.33) no bias estimation was 
reported, while in 3/36 (0.08) cases a Bland-Altman 
like plot analysis was used although it was not 
mentioned as such in methods (37,38,43). Lastly, in 
2/36 (0.06), along with Bland-Altman analysis, the 
bias was estimated through Passing-Bablok re-
gression with 95% confidence intervals (21,41).
With respect to agreement between laboratory 
test results obtained with and without the factor 
applied, the Passing-Bablok regression was used 
in 8/36 (0.22) papers, while in 24/36 (0.67) papers 
no agreement assessment was shown. In 3/36 
(0.08) cases it was used the ordinary least-squares 
regression and in 1 single case (1/36, 0.03) the sim-
ple linear correlation (37,39,42,43). 
Regarding the clinical significance of the pre-ana-
lytical factor, in 16/36 (0.44) papers the authors 
preferred the direct comparison of the corre-
sponding bias with the value of biological variabil-
ity reported in databases. Conversely, in 4/36 (0.11) 
paper it was used a more statistically structured 
approach based on the total change limit (TCL) or 
the reference change value (RCV) (13,14,19,41). 
Interestingly, in those papers that allowed the ret-
rospective estimation of the effect size (7/36 cases, 
0.19), the size of the effect produced on individual 
laboratory test and the corresponding magnitude 
of the bias resulted uncorrelated (Spearman’s ρ = 
0.146, P = 0.142). However, when the clinical signifi-
cance of bias was used as grouping criterion, the 
effect size significantly differed in median magni-
tude (P < 0.001, effect size ρ = 0.59) (Figure 2) 
(21,22,25-29). Particularly, the median was 0.349 
(IQR: 0.228-0.531) and 1.140 (IQR: 0.815-1.700) for 
clinically significant and non-significant bias re-
spectively.   
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Summarizing evidence
Pre-analytical investigations of phlebotomy result-
ed constituting a heterogeneous body of investi-
gations based on the general framework of with-
in-subjects repeated measures design, in which 
the methodological approach showed a certain 
variability even among papers issued by the same 
group of authors. 
First, we recognized some methodological inaccu-
racies that could be considered general issues of 
research articles, and that usually are addressed at 
the level of author guidelines by journals. For in-
stance, the choice of the statistical test (parametric 
or not) was carried out independently from any as-
sessment of the dataset structure (e.g. size, nor-
mality, dispersion). In this regard, we found a lack 
of association between the appropriateness of 
summarization and the journal issuing the paper, 
suggesting that this kind of flaws probably de-
pends on a scarce attention paid by authors to 
that kind of guidelines. 
Second, we observed certain specific drawbacks, 
some of which strictly related to the conceptual 
and statistical framework that characterized this 
kind of studies, and that can be resumed as fol-
lows:
•	 the choice of the population study affecting 
the sample size, with cohorts of healthy volun-
teers ranging below the size of 30
•	 the investigations of more than one laboratory 
test within the same experimental framework 
without an opportune correction, causing an 
inflation of the statistical significance
•	 the lack of calibration (i.e. sample size calcula-
tion based on the least significant detectable 
difference), especially for small sized cohorts 
•	 the use of 2-sample location test (e.g. Student’s 
t-test or Wilcoxon’s test) as a “screening ap-
proach” to a factor in the study
•	 the prevalent use of Bland-Altman plot, with-
out a regression analysis of trend of individual 
differences to assess a proportional effect
•	 the agreement analysis treated as complemen-
tary rather than fundamental for a pre-analyti-
cal investigation, and therefore often ignored 
or sometimes carried out with inappropriate 
methodologies.
Particularly, regarding the last three points, the 
pre-analytical factor, the bias and the agreement 
were usually treated as if there was no relationship 
between them, leading to use multiple tests (often 
redundant) that resulted in a fragmented statisti-
cal framework. Therefore, many studies had po-
tentially non-homogeneous calibration through 
different statistical methods, and thus were poten-
tially at risk of delivering some unreliable results. 
For instance, we noticed that factors showing a 
non-clinically significant bias were associated with 
a smaller effect size when assessed by means of 
2-sample location. Lastly, we also noticed a certain 
lack of standardization in operative procedures re-
ported in the various investigations, and a general 
inhomogeneity regarding how presenting data 
and delivering results to the reader. Thus, based 
on these evidences, we have developed a set of 
recommendations presented in part II of this doc-
ument, aimed to ensure the adequate quality level 
Figure 2. Clinical significance of bias and estimated effect size
The box-plot shows the median and spreading of effect size ac-
cording to the clinical significance of the associated bias (P < 
0.001, effect size ρ = 0.59).
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to researches dealing with pre-analytical issues re-
lated to phlebotomy.
PART II – RECOMMENDATIONS
Setting up the cohort
The nature of subjects within a cohort should be 
chosen in order to address a specific diagnostic is-
sue, rather than a generic laboratory concern. In-
deed, phlebotomy constitutes the essential con-
nection between the clinics and the laboratory di-
agnostics, with venepuncture prompted by a pre-
cise medical question (4). Therefore, the patient-
side perspective should be preferred over the lab-
oratorian-side perspective, even if the investiga-
tion concerns a technical aspect of laboratory pre-
analytics.
The choice of the population in a phlebotomy 
study can make the difference when the results 
are generalized to a different population. For in-
stance, evidences on mechanical factors gathered 
in healthy subjects may not suit oncologic patients 
having chronic lymphocytic leukaemia or under 
tamoxifen treatment, in that they show an abnor-
mal cell fragility (47,48). Conversely, the same co-
hort might suit the investigation on false positives 
in laboratory testing of general population due to 
pre-analytical errors in phlebotomy. 
Calibrating the study 
A study should be meant to detect the meaningful 
effect size of a factor, avoiding both excessive 
(over-powered) or scarce (under-powered) sensi-
tivity (49). Study sensitivity depends on the partic-
ular statistical test adopted to assess significance, 
as well as on the size of the cohort that was cho-
sen to carry out experiments (50-52). As the sam-
ple size has the larger impact since can be more 
easily varied by the researcher, its strict manage-
ment should be meant for achieving the appropri-
ate study calibration and avoiding unreliable re-
sults (see Appendix A) (53). 
Invasive procedures naturally tend to rely on a 
small cohort, and in phlebotomy, some of the ex-
periments even require multiple vein accessioning 
(e.g. the comparison of butterfly versus straight 
needle). Moreover, some medical conditions can 
further complicate the enrolment of patients. For 
instance, it could be easy to adequately size the 
study  when the enrolment concerns subjects un-
der oral anticoagulant therapy with INR between 2 
and 3, but the situation could markedly change at 
higher values of INR (38,43). A practical way of 
properly sizing a study consists in starting from an 
expected magnitude of the effect, that for in-
stance could be estimated by means of retrospec-
tive calculations using previously available data 
(54). Then, the required sample size can be 
achieved inputting the value thereby obtained 
into stand-alone freely-available dedicated soft-
ware as well as on-line web tools, choosing the 
statistical test that is going to be used (55-57). 
Beside calibration, a study should also rely on an 
accurate data validation, achieved assessing the 
dataset shape. A normality test is useful to show 
any eventual significant distortion produced by er-
ratic observations, for instance like the ones that 
can arise due to biological variation (outliers) (58). 
It should be remarked that skewness markedly af-
fects parametric statistics (Student’s t-test), so that 
the choice between parametric and non-paramet-
ric tests should be made carefully and not only 
basing on the sample size (59-61). Indeed, the 
choice of the inappropriate statistical test is re-
sponsible of a deflation of sensitivity, that is al-
ready an issue of small-sized studies (51). There-
fore, data validation should be mandatorily carried 
out as strictly as possible.
Setting the procedures
Procedures used to investigate pre-analytical fac-
tors should be standardized, as the reliability of 
such a study strictly relies on their correct applica-
tion and execution. Indeed, the lack of standardi-
zation could introduce uncontrolled confounding 
factors that might lead to contradictory findings, 
as it was shown happening for the “fasting” condi-
tion or the venous stasis induction (24,62). Thus, if 
a referenced protocol is currently unavailable, the 
author should detail what was performed instead 
of using general terms or descriptions (e.g. “ve-
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nous stasis was induced applying an elastic tourni-
quet at 5 cm above the site of insertion, inducing 
an equivalent pressure to 60 mmHg, holding in 
place for 1 minute after 21G needle insertion” in-
stead of “samples were collected after venous sta-
sis was induced”). 
With respect to laboratory tests used as part of the 
experimental procedures, the recommendation 
concerns the way they should be arranged when 
the study deals with a panel of multiple analytes. 
Actually, this implies that the same cohort is inde-
pendently tested several times (once for each ana-
lyte) within the same experimental framework, a 
fact that rises some concerns on reliability due to 
the probabilistic nature of the statistical assess-
ment (53). In fact, it causes an inflation of the rate 
of falsely significant results, requiring an oppor-
tune correction like an upward adjustment of the 
P-value through appropriate statistical procedures 
(see Appendix B for details) (63,64).   
Maximizing the design
The methodological framework of pre-analytical 
investigations should maximize the reliability and 
consistency of the achieved information. Thus, the 
approach based on assessing the effect of factor, 
the bias and the agreement within the same de-
sign as separate entities through distinct statistical 
methods should be discouraged since inappropri-
ate and unnecessary. 
The two major concerns arising from the use of 
multiple methods are homogeneity of calibration 
and robustness. Recalling what stated earlier on 
statistical power, it is virtually impossible to 
achieve a homogeneous sensitivity for different 
statistical procedures at the same sample size (50-
52). Furthermore, different methods show unlike 
robustness toward the same shape (i.e. outliers) 
and variability (i.e. inhomogeneity of variance) of 
data, that may arise due to an underlying hetero-
geneity of the cohort (65). Thus, combining these 
two factors, a research might show redundant 
tests producing even discordant evidences (see 
further in this section). Instead, the statistical 
framework should avoid any ambiguity, maximiz-
ing the advantage of within-subjects designs that 
allow controlling the intra-individual variability in-
creasing the precision of estimates and in turn the 
study sensitivity (50,52). In this regard, linear mod-
els like regression and especially linear mixed-ef-
fects model (LMEM) should be preferred. 
The LMEM (or multilevel model) is a general case 
of multiple regression (i.e. a regression with more 
than one predictor) suitable to handle the contri-
bution of individual variability in the analysis of 
multiple effects (66,67). It can handle both effects 
that can be experimentally replicated and have 
the same size for all tested subjects (namely 
“fixed”, like two different bore sizes or different 
stasis duration), and effects that lay outside the ex-
perimental control and have a certain variability 
(namely “random”, like the homeostatic point of 
each subject in the study) (66,68). In pre-analytical 
investigations, the two kinds of effects are always 
combined, because planned factors are applied to 
a random set of individuals (28,69). Thereby, LMEM 
can decompose total variability (i.e. variance) into 
components, showing the contribution of within-
subject, analytical (i.e. method imprecision), and 
factor effect (bias) separately. For instance, one 
may plan to investigate the rate of pseudohyper-
kalemia due to needle bore size, and simultane-
ously investigating the effect of age (random ef-
fect), MCV (random effect) and gender (fixed ef-
fect) of the subjects adding the appropriate terms. 
The LMEM is an observation-centred rather than a 
factor-centred framework like ANOVA and repeat-
ed-measures ANOVA (70,71). Thereby, it has other 
two points of strength: a) it can handle missing 
data produced by outliers removal or eventual 
drop outs, and b) it can account for correlation be-
tween observations like the effect of baseline val-
ue on response within the same individual. A ma-
jor (and technically the only one) limitation to the 
use of LMEM is the methodological complexity, 
that demands the appropriate level of statistical 
knowledge to properly set-up the experimental 
design, transferring data into the statistical frame 
and interpreting the results (66).
The Passing-Bablok regression is an in-error varia-
ble method that relies on a non-parametric esti-
mation of coefficients to gain robustness (72-74). 
With respect to Deming model that relies on the 
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least-squares estimates, it is fairly insensitive to 
outliers, and allows to handle single measurement 
for each observation pair ignoring the analytical 
imprecision (75,76). As well as any other regression 
method it shows the agreement between paired 
observations, that is the way they scatter around a 
line with no prevailing effect of one procedure 
over the other. However, being a linear model of 
relationship, it decomposes the observed effect 
into a constant (intercept c) and a proportional 
(slope b) bias (77,78). What is more it relies on con-
fidence interval for assessing significance, accus-
toming researchers and readers to give up the use 
of P-value (79). Limitations of the Passing-Bablok 
model are that it cannot handle multiple factors 
and missing data, as well as it necessitates a high 
correlation between paired observations to hold.
It should be remarked that the use of 2-sample lo-
cation tests (e.g. t-test and non-parametric equiva-
lents) as a means to assess statistical significance 
of a factor, alone or beside regression analysis, 
should be discouraged. Actually, they investigate 
only systematic difference, that is systematic bias 
at an agreement analysis, and can be considered 
reliable just when observations cover a narrow 
range and no significant trend is supposed to arise 
(80,81). Therefore, a paper could report a non-sig-
nificant factor at t-test producing a proportional 
bias instead, confusing the reader.
Assessing clinical significance
The clinical significance of any procedure should 
be always assessed within the statistical frame-
work adopted to test the factor, and reported 
alongside the statistical significance. If the assess-
ment is carried out with linear models (Passing-Ba-
blok regression, LMEM) it is suitable to use the 
RCV, popularized in laboratory medicine by Fraser, 
to get the actual threshold of clinical significance 
(82). If the observed bias is larger than the expect-
ed combined effect of analytical and biological 
variability, then clinical significance is achieved. 
The RCV can be obtained at different levels of the 
laboratory assay knowing the corresponding ac-
tual imprecision of the analytical method by 
means of quality control samples (an example ap-
plied to regression analysis in shown in Appendix 
C). Alternatively, the technically equivalent total 
change limit (TCL) can be used (83). As they both 
depend on the underlying assumption of statisti-
cal normality (same probability of getting an 
equally large positive or negative variation), they 
can be reformulated using a robust non paramet-
ric model in order to better resemble the structure 
of data and gain the appropriate sensitivity (84,85). 
Lastly, the comparison of achieved bias with desir-
able values obtained from databases is another al-
ternative to the use of statistically derived bound-
aries, but it does not take into consideration the 
actual imprecision of the methods used to per-
form experiments (86). 
A concluding remark on statistical methodology 
regards the recommendation to use the difference 
plot (better known as Bland-Altman plot) for bias 
assessment and clinical significance in these stud-
ies. The method was devised to estimate at-a-
glance, by the scatter plot of individual differences 
between paired observations, the 95% limits of 
agreement using the ± 1.96 standard deviation in-
terval around the average bias (87-89). The proce-
dure has the major advantage of computational 
simplicity and visual immediacy, but in order to 
emphasize the random component of bias it con-
strains the modelling of the systematic and pro-
portional components (90). It should be also not 
considered complementary to regression analysis, 
also because procedures based on least squares 
estimate do not return independently distributed 
residuals while the Bland-Altman plot assumes dif-
ferences to behave otherwise (91). Therefore, use 
and interpretation of this kind of plot within a 
framework based upon linear modelling should 
be carefully undertaken. 
Delivering the evidences 
A pre-analytical investigation of phlebotomy 
should aim to deliver information of practical rele-
vance, and thus it should be meant to reach also 
non-academic recipients. This makes accessibility 
a major objective, and the author should take into 
consideration the impact in the decision-making 
of the phlebotomist accessing his research. In this 
http://doi.org/10.11613/BM.2017.020 Biochemia Medica 2017;27(1):177–91 
  185
Ialongo C, Bernardini S. Methodological paradigm of phlebotomy research 
regard, it should be advisable to use P-value be-
side the confidence interval plus the level of clini-
cal significance, as that was shown to produce the 
highest rate of correct interpretation of results 
(92,93).
General recommendations of scientific writing are 
considered mandatorily applied to these studies 
(7). However, two special recommendations con-
cern the section reporting the study discussion. 
First, the authors should take care of emphasizing 
the supposed mechanisms behind the results, es-
pecially with respect their relevance for the actual 
practice of phlebotomy and the current operative 
procedures. Second, they should avoid mention-
ing statistical aspects related to results for not dis-
tracting the reader, leaving such aspects to foot-
notes or appendices to the main text. 
Conclusion
In phlebotomy, operative procedures are funda-
mental for an appropriate patient management 
and clinical testing reliability, and on their simplic-
ity and effectiveness depends the level of compli-
ance they can reach (94,95). The academic research 
has a pivotal role in this, and pursuing standardi-
zation should be considered part of the consolida-
tion process undertaken by any research field 
aware of its scope. Actually, this means attaining 
the unity in the methodological paradigm to 
achieve effectiveness, with a concise, consistent 
and efficient production of cumulative knowledge 
(96). Thus, issuing recommendations (a summari-
zation of which is displayed in Table 2) should be 
regarded as the first step in such a cultural growth.
In this work, we mainly discussed the statistical 
methodology, trying to recognize the specific con-
cerns of pre-analytical investigations of phleboto-
my. When we completed to review the papers, 
that body of publications looked like highly heter-
ogeneous with some redundancies within the sta-
tistical framework. Thereby, we considered a suita-
ble approach pruning the existing framework in-
herited from the method comparison studies, bas-
ing on the evidences that it was not always prop-
erly or sufficiently replicated in all its fundamental 
parts (97). Maybe, since laying in between clinics 
and laboratory, phlebotomy has long struggled to 
gain in scientific literature its own identity and the 
same reputation as laboratory assays. For instance, 
it’s symptomatic that just two out of the six papers 
issued by 1996-2000 used a kind of difference plot, 
and both of them neither mentioned the Bland-
Altman eponymous nor cited the original paper 
(by the way, Scopus showed 3914 citations yet by 
that time) (19,20). Conversely, in the past years, 
mostly the last five (see Figure 1), we observed a 
change in trend and a growing attention payed to-
ward this kind of research. Probably, we owe that 
to the efforts spent for addressing the cardinal role 
and the pre-analytical relevance of phlebotomy in 
modern laboratory medicine, making of it a major 
concern (1,98). 
There are some aspects of this work that should 
be addressed as possible limitations, and for which 
we would provide a justification. Actually, we did 
not structure this work as a systematic review, rely-
ing on PubMed MEDLINE alone, and it could be ar-
gued that a certain bias of partiality arose. Howev-
er, we were concerned with the way the scientific 
information was produced and delivered, and not 
with its use for generating meta-analytical results. 
PubMed represented our objective being a com-
prehensive health information resource that is 
•	 Choose the subjects of your study to address laboratory 
pre-analytics with respect to a precise diagnostic issue, 
considering the limitations and pitfall of results when 
generalized.
•	 Adopt a standard procedure if available to investigate a 
pre-analytical factor, or detail it if there is none available.
•	 Use a statistical framework in order to give consistency 
and unity to the analysis of data, avoiding multiplication 
of methods and inhomogeneous calibration (i.e. minimum 
effect size detectable).
•	 Assess the clinical significance of bias at different levels, 
preferably the same of the internal quality control 
performed on the laboratory tests used for the study.
•	 Ensure accessibility to results and discussion focusing on 
mechanisms, relating to current procedures or guidelines, 
and avoid including any statistical consideration.
Table 2. Recommendations for pre-analytical studies in phle-
botomy
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preferably queried by academic readers over oth-
er databases (99,100). Thus, merging the search re-
sults of different sources would have meant devi-
ating from the perspective of largest part of po-
tential readers, introducing a bias of liberality in-
stead. 
Second, it could be objected that the pruning was 
rather an arbitrary choice of the suitable tech-
niques not based on a consensus, which tended to 
privilege more complicated statistical procedures. 
Actually, the logic was contrasting the unneces-
sary multiplication of methods within the statisti-
cal framework mostly caused by their customarily 
use. For instance, we proposed to carefully handle 
the Bland-Altman plot, reputed a mainstay of the 
comparative paradigm (97). Interestingly, it should 
be noticed that the celebrated simplicity was al-
ready recognized not a guarantee of appropriate-
ness and homogeneity regarding its use and diffu-
sion (101). 
In a future perspective, the critical process initiat-
ed issuing these recommendations should culmi-
nate in the development of a complete chart dedi-
cated to pre-analytical investigations (and not only 
strictly concerning phlebotomy) similar to the 
Standards for Reporting Diagnostic Accuracy’s 
(STARD) chart. Potentially, that would consolidate 
the contribution of this research field to both labo-
ratory quality and patient safety (102). However, 
the adherence to strict requirements represents 
an additional effort in managing a study, that can 
be experienced as impractical if the peer-review-
ing process does not encourage to comply with it 
and the research quality is not exalted by an in-
creased citation rate (103-105). The experience 
maturated with the STARD has shown how much 
all such factors hindered the consolidation of such 
a new paradigm, despite the wide resonance it 
had in the scientific literature (106-109). Obviously, 
there must be correspondence between authors, 
peer-reviewers and journals to let any new con-
cept reaching acceptance and spreading (110-113). 
What outlined above can be nothing but a slow 
process of growth that demands collective aware-
ness and positive disposition to achieve maturity. 
Actually, we need to challenge the safe zone of 
customaries to follow that growth.
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APPENDIX A – Calibrating the study for a robust regression analysis of bias
Any regression model requires to be calibrated on 
the applied range of values, the size of slope 
change to detect and the variability in observa-
tions, and this holds for both parametric and non-
parametric methods (72,73,112). However, the lat-
ter requires simulation studies, so that for Passing-
Bablok method it is suitable to use summarized 
results in tables available through original papers. 
To use the aforementioned tables, it is necessary 
to input the range of any two series of observation 
(since the method is invariant and the two must 
be highly linearly correlated), their dispersion (as 
coefficient of variation, CV%) and the expected 
minimum slope change (as ratio).
Thus, if a series of observations ranges from cmin to 
cmax, then:
Eq.1.1   Crange size = 
Cmax
Cmin
For studies involving a homogeneous population 
it can be suitably used c = 2, specifying that Pass-
ing and Bablok modelled any value 2 ≤ c < 4 as c = 
2 and 4 ≤ c < 8 as c = 4 (73). Then, for a 10% pro-
portional bias, the slope change becomes b = 0.9-
1.1, so that if CV = 2% holds for both series of ob-
servations, a cohort of 30 individuals would be 
suitable to achieve the customarily 80% sensitivity 
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at α = 0.05. However, with a CV as high as 5% with 
all other terms being equal, the same sensitivity 
would be achieved basing on 90 subjects. It should 
be remarked that, Passing and Bablok themselves 
recommended to use always a sample size of 30 at 
least when applying their model (113). 
APPENDIX B - Deflating the level of statistical significance in multiple independent 
testing
The α level represents the testwise probability of a 
false positive result, that is obtaining a P-value < α 
just by chance when the null hypothesis is really 
true. Therefore, the test wise probability of a true 
positive result equals 1 - α, that is 0.95 if α = 0.05 as 
usual. Sometimes, the same experimental frame-
work (same cohort) is used to test a factor on sev-
eral variables independently (A vs. A’, B vs. B’, etc., 
to not confound with multiple post-hoc compari-
sons A vs. A’, A’ vs. A”, A vs. A”), which implies repli-
cating C times the hypothesis testing procedure. 
In plain words, it corresponds to asking whether 
the population has at least one statistically signifi-
cant characteristic among those tested with re-
spect to the same factor. In this case, the experi-
mentwise probability of a false positive outcome 
becomes 1 - (testwise probability of false positive 
result)C = 1 - (1 - testwise probability of true posi-
tive result)C that is:
Eq.2.1   αexperimentwise = 1 – (1 – αtestwise)c
Hence, for 2 tests the experimentwise α = 0.10, for 
4 α = 0.19, but for 10 test it gets as high as α = 0.40.
The Bonferroni correction for deflating α is 
achieved through:
Eq.2.2   αBonferroni testwise = 
αtestwise
C
Instead, the Šidák correction is achieved through:
Eq.2.3   αŠidák testwise = 1 – (1 – αtestwise)1/c
Thus, for 10 independent tests the adjusted test-
wise α returned by both methods would be α = 
0.005, but in case of 20 tests it would get as low as 
α = 0.0025 for Bonferroni and α = 0.003 for Šidák. 
Then, substituting for the adjusted testwise α in 
Eq.2.1, it is possible to obtain the deflated experi-
mentwise α. Hence, applying the method of Šidák, 
the experimentwise significance for 20 tests would 
return α = 1 – (1 – 0.003)20 = 0.058 instead of the 
uncorrected α = 1 – (1 – 0.05)20= 0.642).
APPENDIX C – Using RCV for clinical assessment of linear regression bias
If CVI is the within-subject biological variability 
and CVA the method imprecision, then the RCV 
can be computed according to the formula (82): 
Eq.3.1   RCV = Z × 2 × (CVI2 + CVA2)
Where z is a constant for the level of statistical con-
fidence (1.96 for α = 0.05). For a hypothetical ana-
lyte X (expressed in arbitrary units, au), the litera-
ture reports CVI = 0.13 (13%), and by the internal 
quality control it is known that CVA-LOW = 0.21 
(21%) around the 25 au level, and CVA-HIGH = 0.14 
(14%) around the 85 au. Hence, appropriately sub-
stituting in Eq.3.1, the RCV at α = 0.05 statistical 
significance results ± 0.68 (68%) and ± 0.53 (53%) 
at low and high level respectively.
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Through the Passing-Bablok regression, it is shown 
that an alternative procedure compared to the 
standard for the collection of blood samples 
caused both systematic (c = -6.46 au; 95% CI: -9.22 
to -3.53 au) and proportional (b = 1.16 au; 95% CI: 
1.12 to 1.22 au) bias in the analysis of the analyte X. 
Therefore the final equation to find out the corre-
sponding biased values in the alternative proce-
dure is:
Eq.3.2   biased value = – 6.46 + 1.16 × (reference value)
Using Eq.3.2, at low quality control it was found 
22.5 au with bias (25 - 22.5) / 25 = 0.10 (10%), and 
at high quality control it was 92.1 au with bias (85 - 
92.1) / 85 = - 0.08 (- 8%). Therefore, although statis-
tically significant, no clinical significance was pro-
duced by the alternative collection procedure. 
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